Framycetin (Neomycin B) is an aminoglycoside antibiotic, which is an effective inhibitor of RNase P cleavage activity with Ki of 35 μM. Framycetin competes for specific divalent metal ion binding sites in RNase P RNA. Framycetin inhibited Hammerhead ribozyme with Ki value of 13.5 μM. Framycetin is a 5 "-Azido neomycin B precursor that binds to the Drosha site in Mir-525 and can be used for hepatic encephalopathy and enteropathogenic E. coli infection.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO ≥ 40 mg/mL|
RP-6306 is the only inhibitor of PKMYT1 currently available in the clinic, which is synthetically fatal to CCNE1 amplification, FBXW7 deletion or other specific mutations.
Myxothiazol, an antifungal antibiotic, is an inhibitor of mitochondrial electron transport chain complex III (Complex III or Bc1 complex).
Wheat agglutinin (WGA) is isolated from wheat (Triticum vulgaris, Weat germ), WGA selectively binds to glycoproteins and glycolipids of n-acetylglucosamine (GlcNAc) and n-acetylneuraminine (sialic acid) residues.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.